moxifloxacin has been researched along with etravirine in 2 studies
| Studies (moxifloxacin) | Trials (moxifloxacin) | Recent Studies (post-2010) (moxifloxacin) | Studies (etravirine) | Trials (etravirine) | Recent Studies (post-2010) (etravirine) |
|---|---|---|---|---|---|
| 3,157 | 552 | 1,690 | 572 | 90 | 321 |
| Protein | Taxonomy | moxifloxacin (IC50) | etravirine (IC50) |
|---|---|---|---|
| Chain A, Reverse transcriptase/ribonuclease H | HIV-1 M:B_HXB2R | 0.0021 | |
| Chain B, p51 RT | HIV-1 M:B_HXB2R | 0.0021 | |
| Chain A, Reverse transcriptase/ribonuclease H | HIV-1 M:B_HXB2R | 0.0021 | |
| Chain B, p51 RT | HIV-1 M:B_HXB2R | 0.0021 | |
| ATP-binding cassette sub-family C member 3 | Homo sapiens (human) | 5.1 | |
| Cytochrome P450 1A2 | Homo sapiens (human) | 0.025 | |
| ATP-dependent translocase ABCB1 | Homo sapiens (human) | 7.6 | |
| Cytochrome P450 3A4 | Homo sapiens (human) | 0.019 | |
| Cytochrome P450 2D6 | Homo sapiens (human) | 0.032 | |
| Cytochrome P450 2C9 | Homo sapiens (human) | 0.017 | |
| Gag-Pol polyprotein | Human immunodeficiency virus type 1 (NEW YORK-5 ISOLATE) | 0.37 | |
| Cruzipain | Trypanosoma cruzi | 4 | |
| Multidrug resistance-associated protein 1 | Homo sapiens (human) | 8.5 | |
| Glutamate receptor ionotropic, NMDA 1 | Rattus norvegicus (Norway rat) | 0.01 | |
| Kappa-type opioid receptor | Cavia porcellus (domestic guinea pig) | 0.097 | |
| Glutamate receptor ionotropic, NMDA 2A | Rattus norvegicus (Norway rat) | 0.01 | |
| Glutamate receptor ionotropic, NMDA 2B | Rattus norvegicus (Norway rat) | 0.01 | |
| Glutamate receptor ionotropic, NMDA 2C | Rattus norvegicus (Norway rat) | 0.01 | |
| Glutamate receptor ionotropic, NMDA 2D | Rattus norvegicus (Norway rat) | 0.01 | |
| Reverse transcriptase/RNaseH | Human immunodeficiency virus 1 | 0.2711 | |
| Glutamate receptor ionotropic, NMDA 3B | Rattus norvegicus (Norway rat) | 0.01 | |
| Canalicular multispecific organic anion transporter 1 | Homo sapiens (human) | 7.8 | |
| Glutamate receptor ionotropic, NMDA 3A | Rattus norvegicus (Norway rat) | 0.01 | |
| Broad substrate specificity ATP-binding cassette transporter ABCG2 | Homo sapiens (human) | 6 | |
| Reverse transcriptase | Human immunodeficiency virus 1 | 0.0186 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| De Smedt, G; Hoetelmans, RM; Janssen, K; Kakuda, TN; Lachaert, R; Peeters, M; Schöller-Gyüre, M; Woodfall, B | 1 |
1 review(s) available for moxifloxacin and etravirine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 trial(s) available for moxifloxacin and etravirine
| Article | Year |
|---|---|
Etravirine has no effect on QT and corrected QT interval in HIV-negative volunteers.
Topics: Adolescent; Adult; Anti-HIV Agents; Anti-Infective Agents; Aza Compounds; Confidence Intervals; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Electrocardiography; Female; Fluoroquinolones; Follow-Up Studies; Humans; Male; Middle Aged; Moxifloxacin; Nitriles; Pyridazines; Pyrimidines; Quinolines; Sex Factors | 2008 |